Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on January 30.
Geoff Meacham has given his Buy rating due to a combination of factors surrounding Natera’s recent legal victories and its defensible intellectual property (IP) portfolio. The company’s favorable outcome in a significant patent infringement suit has not only fortified its position but also awarded it substantial damages. This success is indicative of Natera’s ability to protect its market share in the competitive diagnostics market, particularly within the lucrative minimal residual disease (MRD) sector.
Moreover, beyond the courtroom wins, Natera’s comprehensive clinical evidence and numerous publications support the dominance of their Signatera product. Meacham anticipates that these factors, along with expected inclusion in national guidelines and upcoming product catalysts, will significantly contribute to Natera’s growth and market leadership going forward, thus warranting a Buy rating for the stock.
Souda covers the Healthcare sector, focusing on stocks such as Natera, Illumina, and Exact Sciences. According to TipRanks, Souda has an average return of -6.4% and a 41.94% success rate on recommended stocks.
In another report released on January 30, Piper Sandler also assigned a Buy rating to the stock with a $70.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Natera (NTRA) Company Description:
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
Read More on NTRA:
- Jury rules in favor of Natera in patent infringement lawsuit against CareDx
- CareDx found to have not infringed on one Natera patent, infringed on another
- Wolfe reiterates Outperform on Natera after favorable jury decision
- CareDx weakness attributed to ruling in patent fight
- Natera Acquires Invitae’s Prenatal Screening Business
